Overview

A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Esomeprazole
Proton Pump Inhibitors
Criteria
Inclusion Criteria:

- Persisting symptoms of GORD despite previous treatment with a full dose proton pump
inhibitor

- informed consent

- over 18 years of age

Exclusion Criteria:

- Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to
enrolment in the study

- More than 1 other course of PPI treatment in the previous 12 month

- previous use of esomeprazole

- presence of alarm symptoms